YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Points Interested in Relmada Therapeutics, Inc.? Here are five stocks we like better. NDV-01 manufacturing is Relmada's immediate priority as it targets an investigational new drug application (IND) filing by the end of 2026, followed…
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE)…
Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data for its NDV-01 candidate, which showed a…
The following companies are expected to report earnings after hours on 05/12/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Franco-Nevada Corporation (FNV)is reporting for the quarter ending March 31, 2026…
12-Month Phase 2 data in High-Risk NMIBC to be presented Friday, May 15, 2026Phase 3 overview to be presented at Trials-in-Progress session on Sunday, May 17, 2026The Phase 3 “RESCUE” registrational program remains on track to be initiated…
For Immediate Release Chicago, IL – April 6, 2026 – Today, Zacks Equity Research discusses Indivior Pharmaceuticals INDV, Catalyst Pharmaceuticals CPRX, Theravance Biopharma TBPH, Relmada Therapeutics RLMD and Avalo Therapeutics AVTX. Indu…
The drug and biotech sector has been in a recovery mode since mid-2025, after going through a difficult period between 2021 and 2023 backed by strong quarterly results, surging mergers and acquisitions (M&A) activity and pipeline and regul…
Relmada Therapeutics Inc (NASDAQ:RLMD) is among the best psychedelic stocks to buy in 2026. The company has several potential drugs at various stages of development. Its psychedelic drug candidate REL-P11 has completed a Phase 1 safety stu…
(RTTNews) - Relmada Therapeutics, Inc. (RLMD) reported fourth-quarter and full-year 2025 results and highlighted a year of major clinical and corporate progress, led by strong 12-month data for its bladder-cancer candidate NDV-01 and a $16…
Image source: The Motley Fool. Date Thursday, Mar. 19, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Dr. Sergio TraversaChief Medical Officer, Oncology — Dr. Raj S. PruthiChief Financial Officer — Maged S. Shenouda Need…
Relmada Therapeutics logo Key Points NDV-01 showed durable Phase 2 efficacy with a 12-month complete response rate of 76% overall (80% in BCG-unresponsive patients) and high overall CRs (95% any-time) with no progression to muscle-invasive…
Shares of Relmada Therapeutics RLMD rallied 42% in a week after the company announced positive 12-month interim data from its ongoing mid-stage study evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC).…
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system dis…
Quick Read Xenon Pharmaceuticals (XENE) is up 49.6% to $62.76 after azetukalner showed 53.2% seizure reduction, with $716M cash and $56.50 average price target. Relmada Therapeutics (RLMD) rose 61.1% to $7.17 on 92% response rate data, wit…
Relmada Therapeutics (RLMD) said Monday it has struck a deal to sell shares and pre-funded warrants PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Raymond James upgraded Cummins (CMI) to Outp…
Chaay_Tee / iStock via Getty Images Quick Read Friday’s triple witching expiration for options and futures helped the markets close the week on a solid note. The strong move higher by all the major indices may signal the beginning of a tra…
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of…
Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap. RLMD has shown strong technical momentum, gaining 440% since August. Shares have a 100% “Buy” technical opinion f…
Earnings Call Insights: Relmada Therapeutics (RLMD) Q3 2025 MANAGEMENT VIEW * CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development progress" and a "recent successful capital raise." He emphas…
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two indepe…
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indi…
On November 4, 2025, major U.S. stock indexes closed sharply lower, with tech stocks leading the decline and Bitcoin experiencing a notable drop. In such volatile market conditions, investors often seek out opportunities that might offer b…
Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla.,…
As the U.S. stock market navigates the complexities of a government shutdown and fluctuating employment figures, major indices like the Dow Jones have managed to shake off early declines, reflecting resilience amid uncertainty. In such tim…
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Relmada Therapeutics, Inc. is one of them. Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotech company that develops inn…
NEW YORK, NY / ACCESS Newswire / September 16, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day September Small-Cap Conference taking place Wednesday and…
* Relmada Therapeutics (NASDAQ:RLMD [https://seekingalpha.com/symbol/RLMD]) on Tuesday said it has regained compliance with Nasdaq's $1.00 minimum bid price requirement. * The company’s shares maintained a closing bid price of $1.00 or hig…
CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous sy…
Which stocks have an unusual volume on Wednesday? [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PSNYW [https://www.chartmill.com/stock/quote/PSNYW/profile] 25.04% POLESTAR AUTO CLASS C-1 ADS (NASDAQ:PSNYW [https://www.cha…
As the U.S. markets retreat from record highs, investors are keenly watching how economic indicators and Federal Reserve policies might shape future opportunities. In this context, penny stocks—despite their somewhat antiquated name—contin…
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GMHS [https://www.…
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GMHS [https://www.chartmill.com/stock/quote/GMHS/profile] 93.89% Investors celeb…
Earnings Call Insights: Relmada Therapeutics, Inc. (RLMD) Q2 2025 MANAGEMENT VIEW * CEO Sergio Traversa highlighted the addition of two product candidates, NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for compulsiv…
CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indi…
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent D…